Shares of Targacept (TRGT) trade 6.7% higher premarket a day after a Phase 2 trial of the firm's...

|By:, SA News Editor

Shares of Targacept (TRGT) trade 6.7% higher premarket a day after a Phase 2 trial of the firm's TC-5619 drug candidate rattled investors. Adam Feuerstein says the company's promising pipeline helps to keep the name interesting to institutional investors.